Mateos Manteca, M. V., Oriol, A., Martinez-Lopez, J., Gutiérrez Gutiérrez, N. C., Teruel, A., de Paz, R., . . . San Miguel Izquierdo, J. F. (2010). Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial.
Citación estilo ChicagoMateos Manteca, María Victoria, et al. Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Thalidomide, and Prednisone As Induction Therapy Followed By Maintenance Treatment With Bortezomib and Thalidomide Versus Bortezomib and Prednisone in Elderly Patients With Untreated Multiple Myeloma: A Randomised Trial. 2010.
Cita MLAMateos Manteca, María Victoria, et al. Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Thalidomide, and Prednisone As Induction Therapy Followed By Maintenance Treatment With Bortezomib and Thalidomide Versus Bortezomib and Prednisone in Elderly Patients With Untreated Multiple Myeloma: A Randomised Trial. 2010.